Table 1.

Main prognostic factors reported in the MPACT and in PRODIGE 4/ACCORD 11 trials at multivariate analysis

Prognostic factors for metastatic pancreatic patients treated with
Gemcitabine-nab-paclitaxel	FOLFIRINOX
Age < 65 yr	Age > 65 yr
(HR = 0.81; P = 0.019)	(HR = 1.47; P < 0.019)
Hepatic metastases	Hepatic metastases
(HR = 1.81; P < 0.001)	(HR = 1.58; P = 0.051)
Number of metastatic sites > 3	Synchronous metastases
(HR = 1.08; P = 0.86)	(HR = 2.47; P < 0.003)
KPS score, 70-80 vs 90-100	Low baseline albumin level
(HR = 1.60; P < 0.001)	(HR = 1.85; P < 0.001)
Region - Eastern Europe
(HR = 1.22; P = 0.077)

KPS: Karnofsky performance status.